Cargando…

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

BACKGROUND: Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although osimertinib is more effective than the first-generation EGFR-TKIs used for fir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Yuichiro, Naka, Go, Yamaguchi, Yoh, Hashimoto, Masao, Suzuki, Manabu, Izumi, Shinyu, Sugiyama, Haruhito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531095/ https://www.ncbi.nlm.nih.gov/pubmed/33008313 http://dx.doi.org/10.1186/s12885-020-07424-w

Ejemplares similares

Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non‐Small Cell Lung Cancer Harboring Only EGFR Mutations
por: Takeda, Yuichiro, et al.
Publicado: (2020)

Endobronchial hamartoma resected via bronchoscopy using high-frequency electrosurgical snare–Preoperative strategies using virtual bronchoscopy
por: Suzuki, Manabu, et al.
Publicado: (2022)

Usefulness of Jackson mask ventilation during bronchoscopy in patients with acute respiratory failure: A retrospective review
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Infectious Pulmonary Artery Pseudoaneurysm That Resolved with Conservative Treatment
por: Nakayama, Toshihiro, et al.
Publicado: (2022)

Pembrolizumab‐related pancreatitis with elevation of pancreatic tumour markers
por: Kakuwa, Tamaki, et al.
Publicado: (2020)

Re-administration of abatacept for the control of articular symptoms of rheumatoid arthritis during anti-tuberculous therapy
por: Kawamoto, Hironori, et al.
Publicado: (2017)

Refractory Chylothorax and Lymphedema Caused by Advanced Gastric Cancer
por: Nagano, Naoko, et al.
Publicado: (2019)

IgG4-related disease with elevated adenosine deaminase in pleural effusion diagnosed clinically using thoracoscopy under local anesthesia and FDG-PET-CT
por: Tamura, Kentaro, et al.
Publicado: (2020)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
por: Hirokawa, Esuteru, et al.
Publicado: (2021)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
por: Wang, Wenxian, et al.
Publicado: (2016)

A rare case of docetaxel‐induced myositis in a patient with a lung adenocarcinoma
por: Ishida, Akane, et al.
Publicado: (2022)

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
por: Nishio, Makoto, et al.
Publicado: (2019)

Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)
por: Usui, Kazuhiro, et al.
Publicado: (2019)

Diagnosis of miliary nodules as lung adenocarcinoma by cryobiopsy: A case report
por: Morishita, Momoko, et al.
Publicado: (2021)

Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
por: Ueki, Yuriko, et al.
Publicado: (2020)

Evaluation of the efficacy and safety of a new flex‐rigid pleuroscope
por: Ishii, Satoru, et al.
Publicado: (2020)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Suspected Tuberculous Pleurisy and Coronavirus Disease 2019 Comorbidity
por: Yamaguchi, Yoh, et al.
Publicado: (2021)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
por: Arrieta, Oscar, et al.
Publicado: (2020)

Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
por: Le, Xiuning, et al.
Publicado: (2023)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
por: Xu, Ziyi, et al.
Publicado: (2021)

The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain
por: Metzger, Brigitte, et al.
Publicado: (2011)

Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations
por: Shi, Chen, et al.
Publicado: (2023)

A Case of Yellow Nail Syndrome with Dramatically Improved Nail Discoloration by Oral Clarithromycin
por: Suzuki, Manabu, et al.
Publicado: (2011)

Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients
por: Kitazawa, Haruna, et al.
Publicado: (2019)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Clinical usefulness of end‐tidal CO(2) measured using a portable capnometer in patients with respiratory disease
por: Suzuki, Manabu, et al.
Publicado: (2023)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
por: Liu, Yongmei, et al.
Publicado: (2017)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors
por: Ishibashi, Masayuki, et al.
Publicado: (2017)

Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
por: Bruno, Rossella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8s5m6f4prlh2kuuung4scp8i1g